Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Tong J, Luo J, Saldinger PF, Rodgers WH. A Rare Case of Histiocytic Sarcoma Secondary to Gastrointestinal Stromal Tumor in the Stomach: Transdifferentiation or Synchronicity? Case Rep Hematol. 2021;2021:8856649.

Magro CM, Mulvey JJ, Laurence J, Sanders S, Crowson AN, Grossman M, et al. The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series. Br J Dermatol. 2021;184(1):141-150.

Hwang I, Uchida H, Dai Z, Li F, Sanchez T, Locasale JW, et al. Cellular stress signaling activates type-I IFN response through FOXO3-regulated lamin posttranslational modification. Nat Commun. 2021;12(1):640.

Soshnev AA, C Allis D, Cesarman E, Melnick AM. Histone H1 mutations in lymphoma: a link(er) between chromatin organization, developmental reprogramming, and cancer. Cancer Res. 2021.

Huang J, Linares JF, Duran A, Xia W, Saltiel AR, Müller TD, et al. NBR1 is a critical step in the repression of thermogenesis of p62-deficient adipocytes through PPARγ. Nat Commun. 2021;12(1):2876.

Haas T, Callum J, Grottke O, Asmis LM, Cushing MM. Response to Wirtz et al: The impact of blood product ratio and procoagulant therapy on the development of thromboembolic events in severely injured hemorrhaging trauma patients. Transfusion. 2021;61(3):991-992.

Sparano JA, Lee JY, Kaplan LD, Ramos JC, Ambinder RF, Wachsman W, et al. Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma. Haematologica. 2021;106(3):730-735.

Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year. bioRxiv. 2021.

Cejas P, Xie Y, Font-Tello A, Lim K, Syamala S, Qiu X, et al. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021;12(1):5775.

Itkonen HM, Loda M, Mills IG. O-GlcNAc Transferase - An Auxiliary Factor or a Full-blown Oncogene? Mol Cancer Res. 2021;19(4):555-564.